Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT | November 15, 2021 | November 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date November 15, 2021 · Filed November 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 76,087 |
Reported balance
After 2021-11-15 transaction · row 1
1 source rowRow 1 · 2021-11-15 · Sale · Disposed 10,000 · Balance 76,087 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.03, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,543 |
Reported balance
Holding disclosure · report date 2021-11-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,543 F2: Balance in the Abbott Laboratories Stock Retirement Trust as of November 15, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.03, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Balance in the Abbott Laboratories Stock Retirement Trust as of November 15, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2021 Filed Nov 17, 2021 23:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,000 | $130.01 | $1,300,090.00 |
DisclosureSEC source: 0001415889-21-005272 · form4-11172021_031122.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,087 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.03, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 135,925 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-004154 · form4-08312021_020857.xml · derivative · entry 4 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 135,925 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 135,925 | $125.48 | $17,055,189.38 |
DisclosureSEC source: 0001415889-21-004154 · form4-08312021_020857.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,087 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.96 to $125.72, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 135,925 | $38.40 | $5,219,520.00 |
DisclosureSEC source: 0001415889-21-004154 · form4-08312021_020857.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,065 | $121.58 | $615,802.70 |
DisclosureSEC source: 0001415889-21-001207 · form4-03022021_040302.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,076 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 25,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001207 · form4-03022021_040302.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,141 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 71,070 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000895 · form4-02232021_030230.xml · derivative · entry 1 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,070 Underlying: Common Shares · 71,070 shares Expires 2031-02-18 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,690 on February 19, 2022, 23,690 on February 19, 2023, and 23,690 on February 19, 2024. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 38,732 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-005553 · edgar.xml · derivative · entry 6 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,925 Underlying: Common shares · 38,732 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 41,268 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001179110-20-005553 · edgar.xml · derivative · entry 5 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 41,268 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 80,000 | $92.00 | $7,360,104.00 |
DisclosureSEC source: 0001179110-20-005553 · edgar.xml · nonDerivative · entry 3 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,822 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.02, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 38,732 | $38.40 | $1,487,308.80 |
DisclosureSEC source: 0001179110-20-005553 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 41,268 | $48.90 | $2,018,005.20 |
DisclosureSEC source: 0001179110-20-005553 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 365 | $78.91 | $28,802.15 |
DisclosureSEC source: 0001179110-20-004685 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,822 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-004685 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,187 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. F2 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,243 | $79.19 | $415,193.17 |
DisclosureSEC source: 0001179110-20-002924 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,523 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 23,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002924 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,766 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 126,435 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002285 · edgar.xml · derivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,435 Underlying: Common shares · 126,435 shares Expires 2030-02-20 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 42,145 on February 21, 2021, 42,145 on February 21, 2022, and 42,145 on February 21, 2023. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 73,424 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001179110-19-007717 · edgar.xml · derivative · entry 4 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,268 Underlying: Common shares · 73,424 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 73,424 | $81.42 | $5,978,196.76 |
DisclosureSEC source: 0001179110-19-007717 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,938 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.41 to $81.505, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 73,424 | $48.90 | $3,590,433.60 |
DisclosureSEC source: 0001179110-19-007717 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 365 | $79.94 | $29,178.10 |
DisclosureSEC source: 0001179110-19-004523 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,932 Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004523 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,297 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,095 | $77.23 | $393,486.85 |
DisclosureSEC source: 0001179110-19-003118 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,638 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 23,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-003118 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,733 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 115,055 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002644 · edgar.xml · derivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,055 Underlying: Common shares · 115,055 shares Expires 2029-02-21 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,351 on February 22, 2020, 38,352 on February 22, 2021, and 38,352 on February 22, 2022. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $67.12 | $6,712.10 |
DisclosureSEC source: 0001179110-18-011045 · edgar.xml · nonDerivative · entry 5 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,583 F1 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $67.12 | $6,712.01 |
DisclosureSEC source: 0001179110-18-011045 · edgar.xml · nonDerivative · entry 4 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,679 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $67.12 | $6,712.00 |
DisclosureSEC source: 0001179110-18-011045 · edgar.xml · nonDerivative · entry 3 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,779 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,697 | $67.11 | $583,664.37 |
DisclosureSEC source: 0001179110-18-011045 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,879 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $67.12 | $6,712.10 |
DisclosureSEC source: 0001179110-18-011045 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,576 Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 602 | $61.53 | $37,041.06 |
DisclosureSEC source: 0001179110-18-008103 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,676 F2 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008103 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,276 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 332 | $59.92 | $19,893.44 |
DisclosureSEC source: 0001179110-18-005309 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,269 Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005309 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,601 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,413 | $60.55 | $146,107.15 |
DisclosureSEC source: 0001179110-18-003323 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,942 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 12,061 | $60.55 | $730,293.55 |
DisclosureSEC source: 0001179110-18-003323 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,355 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 605 | $60.17 | $36,402.85 |
DisclosureSEC source: 0001179110-18-002540 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,294 F1 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 182,935 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002540 · edgar.xml · derivative · entry 3 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,935 Underlying: Common shares · 182,935 shares Expires 2028-02-15 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 60,979 on 02/16/2019, 60,978 on 02/16/2020, and 60,978 on 02/16/2021. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010109 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 30, 2017 Filed Jul 6, 2017 01:06 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 327 | $48.73 | $15,934.71 |
DisclosureSEC source: 0001179110-17-010137 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,566 F1 · ownership.direct: This Form 4/A correctly reports the reporting person's transaction and beneficial ownership, which was previously reported incorrectly due to a system error. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 602 | $45.66 | $27,487.32 |
DisclosureSEC source: 0001179110-17-008472 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,893 Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-008472 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,495 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 34,424 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001179110-17-005585 · edgar.xml · derivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,424 Underlying: Common shares · 34,424 shares Expires 2027-03-31 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,475 on April 1, 2018, 11,474 on April 1, 2019, and 11,475 on April 1, 2020. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,328 | $45.46 | $60,370.88 |
DisclosureSEC source: 0001179110-17-003668 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,488 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 6,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-003668 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,816 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 20, 2017 Filed Feb 22, 2017 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 605 | $44.69 | $27,037.45 |
DisclosureSEC source: 0001179110-17-002964 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,176 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 112,484 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002964 · edgar.xml · derivative · entry 3 LANE ANDREW H · CIK 0001643735 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,484 Underlying: Common shares · 112,484 shares Expires 2027-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,495 on 02/17/2018, 37,494 on 02/17/2019, and 37,495 on 02/17/2020. Read SEC document |
| June 30, 2016 Filed Jul 5, 2016 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 327 | $38.57 | $12,612.39 |
DisclosureSEC source: 0001179110-16-027356 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,781 Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 602 | $39.63 | $23,857.26 |
DisclosureSEC source: 0001179110-16-025993 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,108 Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-025993 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,710 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.